BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 26725901)

  • 1. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
    Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
    J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.
    Wong DK; Seto WK; Cheung KS; Chong CK; Huang FY; Fung J; Lai CL; Yuen MF
    Liver Int; 2017 Jul; 37(7):995-1001. PubMed ID: 27992681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Nassal M
    Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive biomarkers for chronic hepatitis B virus infection management.
    Charre C; Levrero M; Zoulim F; Scholtès C
    Antiviral Res; 2019 Sep; 169():104553. PubMed ID: 31288041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma.
    Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Tuvin D; Hiotis SP
    J Med Virol; 2016 Feb; 88(2):244-51. PubMed ID: 26174662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients.
    Takkenberg RB; Zaaijer HL; Molenkamp R; Menting S; Terpstra V; Weegink CJ; Dijkgraaf MG; Jansen PL; Reesink HW; Beld MG
    J Med Virol; 2009 Jun; 81(6):988-95. PubMed ID: 19382261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes.
    Lin N; Ye A; Lin J; Liu C; Huang J; Fu Y; Wu S; Xu S; Wang L; Ou Q
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
    Shi M; Sun WL; Hua YY; Han B; Shi L
    PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
    Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
    Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
    Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
    BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus.
    Lee JI; Kim JK; Chang HY; Lee JW; Kim JM; Chung HJ; Kim YS; Lee KS
    J Gastroenterol Hepatol; 2014 May; 29(5):1019-27. PubMed ID: 24325315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.